Neurology

Top Medical News
Diabetes, fertility treatment, family history up autism risk in infants
9 hours ago
A recent Egypt study has identified several maternal and neonatal factors contributing to the risk of autism spectrum disorders (ASD) in infants, including the use of assisted fertility treatments, family medical history, and threatened abortion.
Adult ADHD: Study debates on its possibilities and symptoms
Yesterday
The use of electroencephalogram-based neurofeedback (EEG-NF) can help combat inattention among adolescents and young adults, though its efficacy for controlling hyperactivity or impulsivity remains unestablished, a recent meta-analysis has found.
Old age, comorbidities may delay diagnosis of Guillain-Barré syndrome
2 days ago
Older patients, as well as those with malignancies or cardiovascular diseases, may experience substantial diagnostic delay for Guillain-Barré syndrome (GBS), a recent study has found.
Add-on brivaracetam safe, cuts focal seizure frequency
Jairia Dela Cruz, 4 days ago
Adjunctive therapy with brivaracetam is well tolerated and yields substantial reduction in focal seizure frequency regardless of the number or type of concomitant antiseizure medications used, as reported in a study.
Does your patient have headaches or migraines? Regardless, they can be managed successfully.
Pank Jit Sin, 5 days ago
While everyone has headaches at some point in their life, these episodes can turn severe and even chronic in some individuals. The pain can be debilitating to a point where one may find it difficult to do routine jobs.


Macular RNFL thickness flags future cognitive decline in older Asians
Jairia Dela Cruz, 6 days ago
Macular retinal nerve fibre layer (RNFL) thickness appears to be a useful prognostic biomarker of long-term cognitive decline in older adults, a study from Korea has found.
Special Reports
Product Highlight - Pontevia
16 Mar 2022
Galcanezumab Injection
Shifting paradigms in MS management: Early, optimized interventions improve patient outcomes
04 May 2018
Multiple sclerosis (MS) is one of the most common neurological disorders – affecting over 2.3 million people globally – and it is the leading cause of nontraumatic disability in young adults. However,the availability of supportive resources and services for people with MS is scarce in many regions of the world. In Malaysia, the prevalence of MS is estimated at 2-3/100,000; the current Malaysian clinical practice guidelines on the management of MS recommend disease modifying agents, such as interferon-β and teriflunomide, as first-line therapeutic agents. In this article, Dr Singer - in partnership with Sanofi and the Malaysian Society of Neurosciences - shares his insights into managing MS dynamically, highlighting the importance of early intervention in improving patient outcomes.
Conference Reports
MS patients on certain DMTs may have limited protection from COVID-19 vax
Roshini Claire Anthony, 30 May 2022

The overall rate of hospitalization for COVID-19 is low among patients with multiple sclerosis (MS) treated with disease-modifying therapies (DMTs) who have been vaccinated against COVID-19, according to a prospective study from England. However, patients on ocrelizumab or fingolimod have elevated hospitalization rates.

Keto diet: Is there good evidence in MS?
Elvira Manzano, 23 May 2022
A diet rich in fat but low in carbohydrates, popularly known as the ketogenic or “keto” diet, offers clinical benefits to patients with relapsing multiple sclerosis (MS) in a phase II study. Quality of life (QoL) likewise improved, and so did disability.
Dogs catch yawns more easily from their owners than from strangers.
Tristan Manalac, 22 May 2022
Cognitive decline may be slower among older adults who have been long-time pet owners, reports a study presented at the recently concluded Annual Meeting of the American Academy of Neurology (AAN 2022).
Sustained benefits with ocrelizumab in relapsing-remitting MS
Roshini Claire Anthony, 19 May 2022

Patients with relapsing-remitting multiple sclerosis (RRMS) who have suboptimal response to disease-modifying therapies (DMTs) experienced low disease activity after switching to ocrelizumab, according to interim results of the LIBERTO study.

Reduced risk of psychosis relapse with continued pimavanserin use in patients with dementia
Elaine Soliven, 19 May 2022
Patients with Parkinson’s disease dementia (PDD) who continued treatment with pimavanserin had a lower risk of psychosis relapse compared with those on placebo, according to a post hoc analysis of the HARMONY* trial presented at AAN 2022.
No apparent link between COVID-19 vax and cerebrovascular outcomes
Roshini Claire Anthony, 13 May 2022

Several studies presented at AAN 2022 have revealed a lack of association between COVID-19 vaccination and negative cerebrovascular outcomes.

How does IV edaravone fare for ALS in the real world?
Audrey Abella, 10 May 2022
Intravenous (IV) edaravone seems to continue to provide hope for individuals with amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease with no known cure, according to data presented at AAN 2022.
Product Highlights
CME Modules